VSIR and melanoma: Anti-VISTA antibodies appear to target a pathway that does not overlap with the CTLA-4 and PD-1/PD-L1 pathways,68,69 and some studies have shown that negative immune checkpoint regulation by VISTA represents an important potential mechanism of acquired resistance in melanoma patients who are pre-treated with anti-PD-1.70,71